ASC Therapeutics is a biopharmaceutical company based in the San Francisco Bay Area with subsidiaries in Shanghai and Hong Kong focused on gene and cell therapies that can be life saving for people with severe blood disorders.
We are advancing an integrated and sustainable pipeline driven by 14 years of experience in cellular and genomic technologies that correct the root cause of complex disorders impacting the lives of patients. Key technologies include our AAV gene therapy platform and proprietary genome editing systems to develop transformative gene- and cell-based medicines.
Our development pipeline includes two in-vivo gene and CRISPR therapy programs for Hemophilia A and an off-the-shelf allogeneic cell therapy for acute Graft-versus-Host Disease. Both programs had successful FDA interactions, including IND clearance and orphan drug designations, and will become clinical-stage programs in 2022.